Genentech, a member of the Roche Group, is set to present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 in London on July 12-15. These findings showcase the companies’ ongoing commitment to developing next-generation treatments and diagnostic tests aimed at slowing or stopping the progression of Alzheimer’s disease.